Dimensional Fund Advisors
AGRX

Dimensional Fund Advisors’s Agile Therapeutics AGRX Stock Holding History

Dimensional Fund Advisors’s Portfolio AGRX Stock Details AGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-73
Closed -$373K – 3389
2018
Q1 		$373K Buy
73
+28
+62% +$185K ﹤0.01% 3149
2017
Q4 		$240K Sell
45
-3
-6% -$27.9K ﹤0.01% 3199
2017
Q3 		$427K Hold
48
– – ﹤0.01% 3125
2017
Q2 		$359K Buy
48
+41
+586% +$284K ﹤0.01% 3137
2017
Q1 		$44K Buy
+7
New +$35.2K ﹤0.01% 3282

Other funds holding AGRX

PAI
ProQuest Associates IV Naples, Florida $53M AUM 3.35% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
IA
Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
NIM
Needham Investment Management New York $1.96B AUM 101.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dimensional Fund Advisors's AGRX Position: Q2 2018 in Review

Dimensional Fund Advisors sold out of Agile Therapeutics (AGRX) in Q2 2018, closing a stake of 73 shares — an estimated $373K sold.

Dimensional Fund Advisors first reported a position in AGRX in Q1 2017 and held it in 5 quarters. The position peaked at $427K in Q3 2017. 38 funds tracked by Wall St. Rank hold AGRX as of Q2 2018.

  • Dimensional Fund Advisors reported no remaining Agile Therapeutics position as of Q2 2018 after selling out during the quarter.
  • Dimensional Fund Advisors sold 73 Agile Therapeutics shares in Q2 2018, an estimated $373K.
  • Dimensional Fund Advisors first reported a position in Agile Therapeutics in Q1 2017 and held it in 5 quarters.
  • Dimensional Fund Advisors's Agile Therapeutics position peaked at $427K in Q3 2017.
  • 38 funds tracked by Wall St. Rank held Agile Therapeutics as of Q2 2018.

Based on Dimensional Fund Advisors's 13F filing for Q2 2018, filed 10 Aug 2018.